NEUROVANCE
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD. Neurovance has been funded in a venture capital investment by Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, State of Wisconsin Investment Board (SWIB), and Timothy J. Barberich. It was founded in 2009 and is headquartered in Cambridge, Massachusetts.
NEUROVANCE
Industry:
Biotechnology Clinical Trials Health Care Neuroscience
Founded:
2009-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.neurovance.com
Total Employee:
1+
Status:
Closed
Contact:
(617) 758-0300
Email Addresses:
[email protected]
Total Funding:
31.78 M USD
Technology used in webpage:
SPF Apache Microsoft Exchange Online Office 365 Mail Symantec Secure Site Citrix NetScaler Register.com DNS Confluence Networks
Similar Organizations
Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization.
Good Start Genetics
Good Start Genetics is a molecular genetic information company that has designed a proprietary tech platform to harness the power of NGS.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Novaseek Research
Novaseek Research is a clinical data analytics and biospecimen sourcing, has developed a clinical data network platform for research.
Prothena
Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
VBI Vaccines
VBI Vaccinea is a biopharmaceutical company developing novel technologies that seek to expand vaccine.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Current Employees Featured
Founder
Investors List
Venture Investors
Venture Investors investment in Series A - Neurovance
Venture Investors
Venture Investors investment in Series A - Neurovance
Timothy J. Barberich
Timothy J. Barberich investment in Series A - Neurovance
GBS Ventures
GBS Ventures investment in Series A - Neurovance
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Neurovance
Tekla Capital Management
Tekla Capital Management investment in Series A - Neurovance
H&Q Healthcare Investors
H&Q Healthcare Investors investment in Series A - Neurovance
State of Wisconsin Investment Board
State of Wisconsin Investment Board investment in Series A - Neurovance
State of Wisconsin Investment Board
State of Wisconsin Investment Board investment in Venture Round - Neurovance
GBS Ventures
GBS Ventures investment in Venture Round - Neurovance
Official Site Inspections
http://www.neurovance.com
- Host name: ec2-54-204-226-176.compute-1.amazonaws.com
- IP address: 54.204.226.176
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Neurovance"
Neurovance - Crunchbase Company Profile & Funding
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD. Neurovance has been funded in a venture capital investment by Novartis …See details»
Neurovance Company Profile 2024: Valuation, …
Developer of a triple re-uptake inhibitor designed to address lack of focus, inattention and disorganization in ADHD patients.See details»
Neurovance - Funding, Financials, Valuation & Investors
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.See details»
Neurovance - Products, Competitors, Financials, Employees, …
Neurovance is a privately held, clinical-stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADHD) and related disorders. Neurovance is developing centanafadine …See details»
Otsuka Pharmaceutical to Acquire Neurovance, Inc. Acquisition of ...
Mar 3, 2017 · Neurovance is developing centanafadine (CTN, formerly EB-1020) for the treatment of attention-deficit hyperactivity disorder in adult and pediatric patients. The company is based …See details»
Neurovance Inc - Company Profile and News - Bloomberg Markets
Neurovance Inc. manufactures and designs pharmaceutical drugs and medications. The Company develops pharmaceutical preparations for the treatment of disorder of the central …See details»
Neurovance - Contacts, Employees, Board Members, Advisors
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.See details»
Otsuka Pharmaceutical to Acquire Neurovance, Inc.
Mar 2, 2017 · Neurovance is developing centanafadine (CTN, formerly EB-1020) for the treatment of attention-deficit hyperactivity disorder in adult and pediatric patients. The company is based …See details»
Neurovance, Inc. Company Profile | Braintree, MA | Competitors ...
Find company research, competitor information, contact details & financial data for Neurovance, Inc. of Braintree, MA. Get the latest business insights from Dun & Bradstreet.See details»
Neurovance, Inc. | Insights
Jun 15, 2020 · Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Otsuka Pharmaceutical to Acquire Neurovance, Inc.
Mar 3, 2017 · Neurovance is developing centanafadine (CTN, formerly EB-1020) for the treatment of attention-deficit hyperactivity disorder in adult and pediatric patients. The company is based …See details»
Otsuka Pharmaceuticals acquires Neurovance - 2017-03-02
Acquired Organization: Neurovance Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD. …See details»
Neurovance Announces Agreement to Be Acquired by Otsuka …
Mar 2, 2017 · Under the terms of the agreement, OPC will pay Neurovance $100 million up front in cash, plus up to $150 million in additional payments contingent on achievement of …See details»
Otsuka to acquire Neurovance - Chemical & Engineering News
Mar 13, 2017 · Otsuka Pharmaceutical will pay $100 million up front and up to $150 million in potential milestone payments to acquire Cambridge, Mass.-based Neurovance, a six-year-old …See details»
Otsuka : Pharmaceutical to Acquire Neurovance, Inc.
Mar 2, 2017 · Otsuka Pharmaceutical Co., Ltd. (OPC) today announces an agreement with Neurovance, Inc. (Neurovance) under which OPC has agreed to acquire Neurovance, a …See details»
Neurovance's EB-1020 SR for adult ADHD shows - EurekAlert!
May 8, 2014 · Neurovance, Inc. today announced complete results from its phase 2a pilot study of EB-1020 SR, a non-stimulant, in adult male patients with all subtypes of ADHD (attention …See details»
Neurovance - Crunchbase
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.See details»
NeuroVance | Boost Brain Function & Relieve Stress - MNI Lifestyle
Neuro Vance contains a blend of plant-derived phytochemical ingredients that optimise and support healthy brain function by giving your brain a physiological advantage during times of …See details»
Neurovance - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.See details»